Oslo

• A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Ended recruitment
  2024-518343-38-00 5 2025-02-12 Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
• A research study to investigate the effects of CagriSema compared to placebo in people with type 2 diabetes and painful diabetic peripheral … Ended recruitment
  2023-509662-38-00 4 2025-01-22 Type 2 diabetes and painful diabetic peripheral neuropathy
• A study to investigate the course of synovial hypertrophy in patients with haemophilia A on efanesoctocog alfa prophylaxis Ended recruitment
  2024-512066-33-00 6 2024-12-19 Haemophilia A
• Hidradenitis Suppurativa: Evaluation of lutikizumab in Adult and Adolescent Subjects Ended recruitment
  2024-510730-40-00 5 2024-12-12 Hidradenitis Suppurativa
• A Phase 3 study to evaluate the Efficacy and Safety of Efgartigimod IV in Patients with Acetylcholine Receptor Binding Antibody Seronegative … Ended recruitment
  2024-511796-15-00 5 2024-10-16 Acetylcholine Receptor Binding Antibody Seronegative Generalized Myast
• LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis Ended recruitment
  2024-512676-36-00 10 2024-10-09 Langerhans Cell Histiocytosis
• A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended recruitment
  2023-504753-12-00 5 2024-10-01 Lung Cancer, Non-Small Cell
• SAFETY AND FEASIBILITY OF IRRADIATION AND NIVOLUMAB IN ESOPHAGEAL CANCER (INEC-STUDY) – A PHASE I/II TRIAL Ended recruitment
  2023-510124-77-01 9 2024-09-28 Eosophageal cancer
• DART (19-14434) Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study inves … Ended recruitment
  2022-502640-12-01 9 2024-09-27 Non-small cell lung cancer (NSCLC)
• RElapse from Mrd Negativity As iNdication for Treatment Ended recruitment
  2023-510215-18-00 10 2024-09-26 Multiple myeloma
• A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in … Ended recruitment
  2023-506769-67-00 4 2024-09-04 Moderate to Severely Active Ulcerative Colitis
• Extension trial for adults with high cholesterol who completed a MK-0616 clinical trial Ended recruitment
  2023-504922-20-00 5 2024-08-23 Hypercholesterolemia
• A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High- … Ended recruitment
  2023-510178-15-00 5 2024-07-31 High-risk Large B-cell Lymphoma
• Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736). An open label randomized phase II trial with durvalumab following Stereotacti … Ended recruitment
  2024-512439-54-01 4 2024-07-24 Non-small cell lung cancer (NSCLC)
• HOVON 169 CAD: Phase II trial of Zanubrutinib in primary Cold Agglutinin Disease. CaZa study Ended recruitment
  2023-505746-25-00 4 2024-07-16 Cold agglutinin disease
• Pyridoxine in primary sclerosing cholangitis Ended recruitment
  2023-505155-47-00 4 2024-06-19 Primary sclerosing cholangitis
• TALTEC: A phase II study measuring MRD negativity after bispecific T-cell redirectors TALquetamab and TEClistamab consolidation as part of f … Ended recruitment
  2023-508212-38-00 4 2024-06-11 Multiple Myeloma
• A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu … Ended recruitment
  2022-502781-24-01 5 2024-06-05 ASCVD - Atherosclerotic Cardiovascular Disease
• A trial to learn if rilvegostomig with chemotherapy given after surgery is safe in people with biliary tract cancer and works to delay when … Ended recruitment
  2023-506054-20-00 5 2024-06-05 Adenocarcinoma of the biliary tract (intrahepatic or extrahepatic chol
• Comparison between rituximab plus zanubrutinib versus rituximab monotherapy in untreated splenic marginal zone lymphoma patients Ended recruitment
  2023-503755-10-00 5 2024-05-17 Splenic marginal zone lymphoma
• Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis Ended recruitment
  2022-502238-22-00 5 2024-05-14 Ulcerative Colitis
• A study to determine if ALXN2220 is effective, safe, and tolerable in adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Ended recruitment
  2023-506669-70-00 5 2024-04-30 Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
• Phase III Trial of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed vs. Investigator’s Choice of the Standard of Care … Ended recruitment
  2023-503231-17-00 5 2024-04-26 Unresectable Pleural Mesothelioma
• A Phase III Study to assess efficacy, safety, and tolerability of Zibotentan combined with Dapagliflozin, compared to Dapagliflozin, in pati … Ended recruitment
  2023-504124-26-00 5 2024-04-04 Chronic Kidney Disease and High Proteinuria

Showing 289–312 of 508 trials